Genetic changes in ovarian cancer

Annals of Medicine

Volumn 27, Issue 1, 1995, Pages 73-78

  Pejovic, Tanja ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Genetic changes; Karyotypic abnormalities; Ovarian cancer

Indexed keywords

CANCER GENETICS; CARCINOGENESIS; CHROMOSOME DELETION; CHROMOSOME LOSS; CHROMOSOME TRANSLOCATION; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; KARYOTYPE; METASTASIS; MOLECULAR GENETICS; OMENTUM; ONCOGENE; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; TRISOMY; TUMOR SUPPRESSOR GENE;

FEMALE; GENES, TUMOR SUPPRESSOR; HUMAN; KARYOTYPING; ONCOGENES; OVARIAN NEOPLASMS; SUPPORT, NON-U.S. GOV'T;

EID: 0028960676     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899509031940     Document Type: Article

References (42)

1. The clonal evolution of tumour cell population
2. Oncogenes, antioncogenes, and the molecular basis of multistep carcinogenesis
3. Evolution of tumours and the impact of molecular oncology
4. The molecular genetics of cancer
5. Molecular themes in oncogenesis
6. Hereditary cancer, oncogenes, and antioncogenes
7. Chromosome aberrations in 35 primary ovarian carcinomas
8. Cytogenetic studies of epithelial ovarian carcinoma
9. Cytogenetic study of solid ovarian tumours
10. Numerical chromosome abnormalities associated with early clinical stages of gynecologic tumours
11. Specific regulation of the c-myc gene by lymphocyte mitogenes and platelet-derived growth factor
12. Prognostic value of c-myc protooncogene overexpression in early invasive carcinoma of the cervix
13. Alterations of either c-erbB-2 (neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor prognosis
14. Amplification of c-myc proto-oncogene in primary tumours, metastases and blood leukocytes of patients with ovarian cancer
15. C-myc amplification in ovarian cancer
16. Protooncogene amplification and tumour ploidy in human ovarian neoplasms
17. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
18. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial, ovarian cancer
19. c-erbB-2 oncogene expression in ovarian cancer
20. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: a multivariate analysis
21. First expirience with FGF-3 (INT2) amplifiacation in women with epithelial ovarian cancer
22. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1
23. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
24. Deletions of a DNA sequence in retinoblastomas and mesenchymal tumours: organization of the sequence and its encoded protein
25. An analysis of abnormalities of the retinoblastoma gene in human ovarian and endometrial carcinoma
26. The p53 tumour suppressor gene
27. Mutations of the p53 gene occur in diverse human tumour types
28. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer
29. p53 gene mutations and protein accumulation in human ovarian cancer
30. p53 mutation is a common genetic event in ovarian carcinoma
31. p53 mutations in human cancers
32. Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer
33. Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma
34. Allelic loss on chromosome 17 in human ovarian cancer
35. Bilateral ovarian carcinoma: cytogenetic evidence of unicentric origin
36. Unifocal origin of advanced human epithelial ovarian cancers
37. Clonal origin of epithelial ovarian cancer: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation
38. Hereditary ovarian cancer. Pedigree studies, part II
39. Linkage of early-onset breast cancer to chromosome 17q21
40. Familial breast-ovarian cancer locus on chromosome 17q12-q23